Combining expertise across borders to promote Precision Cancer Medicine in Europe. PRIME-ROSE - Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials - is a European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. PRIME-ROSE will run for five years (2023 – 2028), and the consortium consists of altogether 24 partners, including nine beneficiaries and fifteen associated partners. In addition, PRIME-ROSE is part of the Cancer Mission cluster of projects on Diagnosis and Treatment.
The pan-European PRIME-ROSE project is led by Professor Kjetil Taskén, Head of Institute for Cancer Research at Oslo University Hospital Comprehensive Cancer Centre in Norway. The PRIME-ROSE vision is access to affordable Precision Cancer Medicine (PCM) that prolongs life at the best quality possible for all cancer patients.
The project contains eight work packages (WPs): WP1 is about data aggregation whereas WP2 is focusing on randomized, synthetic control cohorts. In WP3 the focus is to initiate and run expansion cohorts whereas WP4 is about harmonisation of off-label use and repurposing medicines. WP5 is about EU implementation in everyday practice and in WP6 the focus is social innovation for access to precision cancer medicine. WP 7 is management and coordination of the project and finally, WP 8 is about dissemination.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Ullernchausséen 70, Oslo,0379,norway
- Industry
- Medical Practices
- NAICS
-
Ambulatory Health Care ServicesOffices of Other Health PractitionersOutpatient Care CentersOther Ambulatory Health Care ServicesOffices of All Other Health PractitionersOutpatient Mental Health and Substance Abuse CentersAll Other Ambulatory Health Care ServicesOffices of PodiatristsBlood and Organ BanksAll Other Miscellaneous Ambulatory Health Care Services
- HQ
- Oslo
- Competitors
- EUnetCCC - European Network of Comprehensive Cancer Centres, PCM4EU - Personalised Cancer Medicine for all EU citizens, MPNEurope, ProTarget Study, eCAN Plus Joint Action, Consell de la Cultura de Barcelona, AUGMA Group, The Cancer Drug Development Forum (CDDF), Villa Primerose, IHI GREG.
Prime-Rose Questions
Prime-Rose's LinkedIn profile is https://no.linkedin.com/company/prime-rose
Prime-Rose has
3 employees.
View email and phone details for 3
employees at Prime-Rose.
Prime-Rose's industry is
Medical Practices
Prime-Rose's top competitors are
Eunetccc - European Network Of Comprehensive Cancer Centres,
Pcm4eu - Personalised Cancer Medicine For All Eu Citizens,
Mpneurope,
Protarget Study,
Ecan Plus Joint Action,
Consell De La Cultura De Barcelona,
Augma Group,
The Cancer Drug Development Forum (Cddf),
Villa Primerose,
Ihi Greg.
Prime-Rose's categories are Medical Practices
Prime-Rose's founding year is 2023
